Arbutus Biopharma Corporation (NASDAQ: ABUS) and Aptose Biosciences (NASDAQ:APTO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, dividends, profitability, earnings and valuation.
Volatility and Risk
Arbutus Biopharma Corporation has a beta of 1.01, suggesting that its share price is 1% more volatile than the S&P 500. Comparatively, Aptose Biosciences has a beta of 1.81, suggesting that its share price is 81% more volatile than the S&P 500.
This is a summary of recent ratings and target prices for Arbutus Biopharma Corporation and Aptose Biosciences, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Arbutus Biopharma Corporation||0||0||5||0||3.00|
Arbutus Biopharma Corporation presently has a consensus price target of $15.00, indicating a potential upside of 165.49%. Aptose Biosciences has a consensus price target of $7.00, indicating a potential upside of 341.14%. Given Aptose Biosciences’ higher probable upside, analysts clearly believe Aptose Biosciences is more favorable than Arbutus Biopharma Corporation.
Insider and Institutional Ownership
67.0% of Arbutus Biopharma Corporation shares are owned by institutional investors. Comparatively, 4.6% of Aptose Biosciences shares are owned by institutional investors. 10.0% of Arbutus Biopharma Corporation shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Earnings & Valuation
This table compares Arbutus Biopharma Corporation and Aptose Biosciences’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Arbutus Biopharma Corporation||$1.85 million||168.05||-$65.74 million||($5.13)||-1.10|
|Aptose Biosciences||N/A||N/A||-$12.87 million||($0.73)||-2.17|
Aptose Biosciences has higher revenue, but lower earnings than Arbutus Biopharma Corporation. Aptose Biosciences is trading at a lower price-to-earnings ratio than Arbutus Biopharma Corporation, indicating that it is currently the more affordable of the two stocks.
This table compares Arbutus Biopharma Corporation and Aptose Biosciences’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Arbutus Biopharma Corporation||N/A||-28.97%||-21.71%|
Arbutus Biopharma Corporation beats Aptose Biosciences on 7 of the 11 factors compared between the two stocks.
About Arbutus Biopharma Corporation
Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV). It is developing a pipeline focused on advancing Ribo Nucleic Acid interference therapeutics (RNAi) using its Lipid Nanoparticle technology. The Company’s lead RNAi HBV candidate, ARB-1467, eliminates HBV surface antigen expression in patients chronically infected with HBV. ARB-1467 is being developed as a multi-component RNAi therapeutic that targets various sites on the HBV genome. It is also developing small molecule covalently closed circular deoxyribonucleic acid (cccDNA) formation inhibitors, multiple small molecule orally bioavailable inhibitors of HBV surface antigen production and secretion, cccDNA epigenetic modifiers and stimulator of interferon genes agonists.
About Aptose Biosciences
Aptose Biosciences Inc. (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities. The Company develops therapeutics focused on epigenetic processes and signal transduction abnormalities at the edge of cancer research, coupled with companion diagnostics to identify the optimal patient population for its products. The Company’s APTO-253 is a small molecule that can induce expression of the genes that codes for the Kruppel-like factor 4 (KLF4) master transcription factor and the p21 cell cycle inhibitor protein.
What are top analysts saying about Arbutus Biopharma Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Arbutus Biopharma Corporation and related companies.